Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amiodarone for Prevention of Postoperative Atrial Fibrillation in Minimally Invasive Esophagectomy
NCT06067438Phase 2Recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jun 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amiodarone in Atrial fibrillation (AFib) (2 arms), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Development of atrial fibrillation (AF) at 7 days. Started Jun 2024; status: recruiting.
02
Drugs
amiodarone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06067438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06067438.